Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.62 |
| ▸ | CTSK | P43235 | 1/20 | 0.62 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.52 |
| ▸ | GPR88 | Q9GZN0 | 5/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21237658 | 0.94 | CTSS (0.58) | CTSSCTSKSCN9AGPR88S1PR3 | |
| SCHEMBL15671568 | 0.86 | CTSK (0.67) | CTSSCTSKSCN9AGPR88S1PR3 | |
| SCHEMBL15671569 | 0.86 | CTSK (0.67) | CTSSCTSKSCN9AGPR88S1PR3 | |
| SCHEMBL4200905 | 0.86 | CTSS (0.53) | CTSSCTSKMAOBKMT2AL3MBTL1 | |
| SCHEMBL17137905 | 0.84 | CTSS (0.64) | CTSSCTSKSCN9AGPR88S1PR3 | |
| SCHEMBL17137904 | 0.84 | CTSS (0.64) | CTSSCTSKSCN9AGPR88S1PR3 | |
| SCHEMBL17137903 | 0.84 | CTSS (0.64) | CTSSCTSKSCN9AGPR88S1PR3 | |
| SCHEMBL12880513 | 0.83 | CTSK (0.67) | CTSSCTSKSCN9AGPR88S1PR3 | |
| SCHEMBL5552377 | 0.83 | CTSS (0.52) | CTSSCTSKSCN9AS1PR3GRM7 | |
| SCHEMBL20418678 | 0.82 | CTSK (0.66) | CTSSCTSKSCN9AGPR88S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4342473-A2 | COMPOUNDS USEFUL IN HIV THERAPY | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-03-27 | — | — | EP | disclosed |
| US-20240051972-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-02-15 | — | — | US | disclosed |
| US-11873310-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-01-16 | — | — | US | disclosed |
| US-11492361-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-11-08 | — | — | US | disclosed |
| US-20220119417-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119417-A1 | Compounds Useful in HIV Therapy | CD4, CCR5, ABCB1 | CTSS 1451/4885CTSK 2213/4885SCN9A 3829/4885 |
| US-20240051972-A1 | Compounds Useful in HIV Therapy | CD4, CCR5, ABCB1 | CTSS 1451/4885CTSK 2213/4885SCN9A 3829/4885 |
| US-11873310-B2 | Compounds useful in HIV therapy | CD4, CCR5, ABCB1 | CTSS 1451/4885CTSK 2213/4885SCN9A 3829/4885 |
| US-11492361-B2 | Compounds useful in HIV therapy | CD4, CCR5, ABCB1 | CTSS 1287/4885CTSK 2101/4885SCN9A 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.